Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Teva Pharmaceutical IndustriesFRA:TEV -1.07%58 Days Inventory is 143.41 as of Mar. 2026, which is 18% below its 10-year median of 175.20. GuruFocus rates FRA:TEV with a GF Score™ of 58/100 and a GF Value™ of €17.94 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 923 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks better than 58.5% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Teva Pharmaceutical Industries's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.64.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Teva Pharmaceutical Industries's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.79.
Teva Pharmaceutical Industries (FRA:TEV) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Teva Pharmaceutical Industries's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Teva Pharmaceutical Industries's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Teva Pharmaceutical Industries Days Inventory Related Terms
Teva Pharmaceutical Industries Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries Days Inventory Chart
FRA:TEV vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Days Inventory distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries (FRA:TEV) has a Days Inventory of 143.41 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Teva Pharmaceutical Industries and its competitors. This is 18% below median its historical median of 175.20. Over the past decade, Teva Pharmaceutical Industries' Days Inventory has ranged from 135.71 to 181.09. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #383 out of 923 companies in the Drug Manufacturers industry, placing it in the top 41.5%.
Is Teva Pharmaceutical Industries' Days Inventory too high?
Teva Pharmaceutical Industries' current Days Inventory of 143.41 is 18% below median its 10-year median of 175.20. Over the past 10 years, this metric has ranged from a low of 135.71 to a high of 181.09. The Drug Manufacturers industry median Days Inventory is 164.38. Teva Pharmaceutical Industries' value of 143.41 is 12.8% below this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #383 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Teva Pharmaceutical Industries has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #383 out of 923 companies for Days Inventory. This puts Teva Pharmaceutical Industries in the upper half of its industry. The industry median Days Inventory is 164.38. Teva Pharmaceutical Industries' value of 143.41 is 12.8% below this benchmark. Historically, Teva Pharmaceutical Industries' own Days Inventory has ranged from 135.71 to 181.09 over the past decade. While the company's 10-year median is 175.20 vs. the industry median of 164.38, Teva Pharmaceutical Industries has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current Days Inventory of 143.41 is 12.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current Days Inventory is 143.41, which is 18% below median its own 10-year median of 175.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (FRA:TEV) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.94, compared to a current price of €27.80 — trading 55% above its estimated fair value. The current Days Inventory is 143.41, which is 18% below median its 10-year median of 175.20 and 12.8% below the Drug Manufacturers industry median of 164.38. Teva Pharmaceutical Industries' overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Teva Pharmaceutical Industries (FRA:TEV), the current Days Inventory is 143.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (FRA:TEV) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of €27.80 is trading 55% above its estimated GF Value™ of €17.94.
GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.
Key valuation signals for FRA:TEV:
Days Inventory: 143.41 (18% below median its 10-year median of 175.20)
GF Value™: €17.94 vs. price of €27.80 (55% above fair value)
Industry Position: 12.8% below the Drug Manufacturers median (#383 of 923)
No single metric tells the full story. See the FRA:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical Industries Business Description
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
58GF Score
Get the complete analysis for FRA:TEV
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TEV has been successfully added to your 
